PMEF
BEAM icon

Point72 Middle East FZE’s Beam Therapeutics BEAM Stock Holding History

Point72 Middle East FZE’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-893
Closed -$34.9K – 1658
2022
Q4 		$34.9K Buy
+893
New +$40K ﹤0.01% 1532

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Middle East FZE's BEAM Position: Q1 2023 in Review

Point72 Middle East FZE sold out of Beam Therapeutics (BEAM) in Q1 2023, closing a stake of 893 shares — an estimated $34.9K sold.

Point72 Middle East FZE first reported a position in BEAM in Q4 2022 and held it in 1 quarter. The position peaked at $34.9K in Q4 2022. 206 funds tracked by Wall St. Rank hold BEAM as of Q1 2023.

  • Point72 Middle East FZE reported no remaining Beam Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 893 Beam Therapeutics shares in Q1 2023, an estimated $34.9K.
  • Point72 Middle East FZE first reported a position in Beam Therapeutics in Q4 2022 and held it in 1 quarter.
  • Point72 Middle East FZE's Beam Therapeutics position peaked at $34.9K in Q4 2022.
  • 206 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2023.

Based on Point72 Middle East FZE's 13F filing for Q1 2023, filed 15 May 2023.